Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Intangible Assets, net

Intangible Assets, net

3 Months Ended

Mar. 31, 2026

7. Intangible Assets, net

The Company’s finite-lived intangible assets consist of intangible assets acquired by Journey. The table below provides a summary of the Journey intangible assets for the periods presented:


		Estimated Useful		March 31,			December 31,
($ in thousands)		Lives (Years)		2026			2025
Intangible assets – product licenses		3 to 15		$	52,925		$	52,925
Accumulated amortization					(23,303)			(22,177)
Accumulated Impairment loss					(3,143)			(3,143)
Net intangible assets				$	26,479		$	27,605

For the three months ended March 31, 2026 and 2025, Journey’s amortization expense related to its product licenses was $1.1 million and $1.1 million, respectively.

In December 2025, Journey received FDA approval for the anti-itch product acquired in 2020. Prior to FDA approval, the anti-itch product had been presented as an intangible asset not yet placed in service totaling $3.9 million. Journey began amortizing the anti-itch intangible asset in January 2026.

The future amortization of intangible assets is as follows:


		Total
For the years ended: ($ in thousands)		Amortization
Remainder of 2026		$	2,906
2027			3,338
2028			3,159
2029			3,159
2030			3,159
Thereafter			10,758
Total		$	26,479